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Purposes - This study was conducted to investigate whether oxidative stress 
and Endothelial-to-Mesenchymal Transition (EndMT) may be part of the 
molecular machinery inducing vascular damage in systemic sclerosis (SSc). 
The possibility that iloprost, a drug commonly used in SSc therapy, might 
modulate the above-mentioned biological phenomena was also investigated. 
Results - Sera from SSc patients markedly increased ROS levels, 
proliferation, and collagen synthesis in human pulmonary microvascular 
endothelial cells (HPMECs). Interestingly, SSc sera taken after 5 hours of 
iloprost infusion could attenuate ROS levels and collagen synthesis.  
Preliminary results show that SSc sera induced the conversion of ECs into 
myofibroblasts through decreasing the endothelial marker, von Willebrand 
Factor, and increasing α-smooth muscle actin, the myofibroblastic marker. 
Conclusion - Exposition of HPMECs to pro-oxidant factors present in SSc 
sera increased disease-associated physio-pathological phenomena such as 
intracellular ROS levels and collagen synthesis. Reduction of the above-
mentioned phenomena by iloprost suggests a potential antioxidant effect of 
this drug. Preliminary data demonstrate the presence of an SSc sera-induced 
EndMT, indicating this phenotypic shift as an important etiological 
mechanism of SSc-associated vascular damage and a potential therapeutic 
target to inhibit obliterative vascular disorder and tissue fibrosis. 
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1. INTRODUCTION 
1.1. Systemic sclerosis 
Systemic sclerosis (scleroderma, SSc) is a complex multisystem autoimmune 
disease of unknown etiology characterized by dysregulated immune system, 
progressive fibrosis of skin and visceral organs in which extensive vascular 
alterations are prominent and severe [41]. There are two major subgroups in 
the commonly accepted classification of systemic sclerosis: limited cutaneous 
systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc). 
The degree of skin fibrosis, immunological profile, and microvascular 
dysfunction determines this clinical classification of the disease [51]. In 
lcSSc, skin fibrosis is restricted to the fingers, distal extremities and face, 
whereas in dcSSc, the trunk and proximal extremities are also affected. In 
patients with lcSSc, Raynaud‘s phenomenon is present for several years 
before fibrosis appears, whereas patients with dcSSc have rapid disease 
progression with extensive skin changes and early development of visceral 
organ complications [2].  Autoantibodies are not only predictive value for 
clinical evaluation and prognosis but also signs to distinguish between lcSSc 
and dcSSc. lcSSc is commonly associated with centromere-specific antibodies 
which occur in 50 to 90% of patients, whereas dcSSc is more often associated 
with topoisomerase I-or RNA polymerase III-specific antibodies [52, 112]. 
This classification can be useful, but none of the proposed classifications 
sufficiently reflects the heterogeneity of the clinical manifestations of 
systemic sclerosis. Some individuals present with hallmark clinical and 
serological features of systemic sclerosis in the absence of detectable skin 
involvement; others manifest the overlap of systemic sclerosis with another 
connective tissue disease, such as lupus erythematosus, rheumatoid arthritis, 
polymyositis . 
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Systemic sclerosis can cause severe dysfunction and failure of almost any 
internal organ. Major organ involvement leads to decreased survival in SSc. 
Pulmonary fibrosis and pulmonary arterial hypertension (PAH) cause more 
than half of all SSc-related deaths. In addition, severe complications of the 
kidneys, heart, lungs, and gastrointestinal tract generally develop within 3 
years of disease onset, particularly in patients with dcSSc [85].  
 
Figure 1.1. Organ complications associated with systemic sclerosis. The uncontrolled 
fibrosis and scaring of the skin and internal organs in systemic sclerosis leads to severe and 
sometimes life-threatening complications. The average frequency of the specific 
complications is indicated in parentheses. PAH, pulmonary arterial hypertension [2]. 
1.1.1. Epidemiology 
The results of studies of prevalence and incidence estimates of SSc show a 
substantial variation across geographic regions. Prevalence and incidence of 
SSc appears to be greater in populations of European ancestry and lower in 
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Asian groups. Lower estimates of prevalence (<150 per million) and 
incidence (<10 per million per year) have been recorded in northern Europe 
and Japan, whereas higher estimates of prevalence (276-443 per million) and 
incidence (14-21 per million per year) have been reported in southern Europe, 
North America and Australia [7]. The 2013 revised classification criteria - the 
American College of Rheumatology (ACR)-European League Against 
Rheumatism (EULAR) criteria include patients with centromere-specific 
antibodies and limited cutaneous involvement. As a result, the estimated 
prevalence of SSc based on the ACR-EULAR classification criteria was much 
higher than previously published estimates [59].  
Like other connective tissue diseases, SSc is sex dependent and occurs more 
common in women. Female/male ratio ranging from 3:1 to 14:1 and it occurs 
more frequently in the fourth or fifth decades of life. However, male sex has 
been consistently shown to be a poor prognostic factor in SSc. In addition, 
race and ethnic groups are related to distinct phenotypic profiles, and there is 
a trend towards less favorable outcomes in Africa American patients.  
1.1.2. Endothelial Dysfunction in Systemic sclerosis 
In SSc, the vasculopathy is one of the earliest pathological events, 
characterized by endothelial cell activation, and altered vascular tone. The 
fact that the vascular manifestations consistently precede tissue fibrosis 
suggests that microvascular endothelial cells (MVECs) are the primary target 
in this disease. The pathological alterations are accompanied by the presence 
of proinflammatory cytokines and angiogenic regulatory factors, and the loss 
of redox control. This complex interaction involves in a number of cells types, 
particularly the endothelial cells. The vascular endothelium provides a 
compatible interface to facilitate blood circulation as well as a multifunctional 
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interface between blood and all internal organs [1]. The vascular endothelium 
participates in regulating coagulation and fibrinolysis, permeability, 
vasomotion, and inflammation. The term endothelial dysfunction is most 
often used to symbolize impairment of endothelium-dependent vasodilation; 
however, a more expanded definition also includes endothelial interactions 
with leukocytes, platelets, and regulatory substances [3]. 
The most prominent clinical vascular dysfunction in SSc is linked to 
dysregulation of vascular tone leading to vascular spasm and reduced blood 
flow. An imbalance between the levels of vasoconstrictor and vasodilator 
mediators is attributed for endothelial dysfunction in SSc. Among these 
vasodilator agents, nitric oxide (NO), produced by endothelial cells (ECs) is 
one of the most potent vasodilator. In SSc, the defects in NO production by 
endothelial nitric oxide synthetase reduce microvascular endothelial cells 
(MVECs) survival and promote apoptosis. Moreover, endothelin-1 (ET-1), a 
potent vasoconstrictor peptide originally isolated from ECs is upregulated in 
SSc sera and tissues. The imbalance between vasodilator and vasoconstrictor 
signals leaves MVECs vulnerable to apoptosis and promotes an environment 
of ischemia, hypoxia, and profibrosis.  
Hypoxia is a possible trigger that mediates MVECs lesions. Hypoxia followed 
by reperfusion induces an inflammatory process and oxidative stress that 
leads to cellular injury. Human MVECs exposing to intermittent hypoxia 
induced the dysfunction of MVECs, associated with an increase in oxidative 
stress. Intriguingly, using antioxidants prevents the effect of hypoxia on 
MVECs.  
It is widely accepted that there are defects of angiogenesis and vasculogenesis 
in SSc. Angiogenesis and vasculogenesis are processes in which new vessels 
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are formed from preexisting vessels and de novo vessels, respectively. These 
defects indicate defective role of MVECs differentiation in two processes. Of 
interest, vascular endothelial growth factor (VEGF) is a very potent 
angiogenic factor that is overexpressed in skin and sera of SSc patients, but 
there is evidence suggesting that VEGF receptor may be impaired in the cells 
based on the observation that MVECs isolated from SSc patients show 
reduced response to VEGF in vitro. In addition, failed release of bone 
marrow-derived progenitor cells, which have the potential to initiate vascular 
repair has been identified in SSc patients. The failure to compensate for 
vascular injury eventually leads to accumulative loss of capillaries and 
arterioles, resulting in the well-known vascular complications: painful ulcers 
on the digits, scleroderma renal crisis occurs in the kidneys, and PAH occurs 
in the lungs [81].  
There appears to be a complex cross talk between MVECs, fibroblasts, and 
leukocytes, especially in early phases of SSc. It is suggested that junctional 
adhesion molecules (JAMs) are important elements in this interaction. The 
levels of JAM-A are unregulated in MVECs especially in early stage SSc, and 
the soluble JAM-A and JAM-C levels are higher in early stage SSc [80]. This 
underlines the role of JAMs in activating MVECs, particularly in early stage 
SSc in which there are more inflammatory infiltrates around the blood 
vessels. 
Finally yet importantly, MVECs may activate fibroblasts and the immune 
system. As a result, activated fibroblasts precede the overproduction of 
collagen and other compartments of extracellular matrix (ECM). 
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Figure 1.2. Pathogenesis of SSc vasculopathy. Endothelial injury and dysfunction are 
initiated by the actions of free radicals or chemical and microbial agents that injure the 
endothelium, either directly or indirectly. This injury is also initiated by the induction of 
immune activation and the generation of autoantibodies and activated cellular immunity. 
The vascular injury activated platelet and coagulation pathways, which results in vascular 
microthrombosis. The resulting vasculopathy is associated with intimal hyperplasia in the 
small arterioles, and the ensuing luminal narrowing results in tissue hypoxia and chronic 
ischemia. Released vascular products, in association with hypoxia and ischemia, 
collectively contribute to the activation of resident fibroblasts, which in turn perpetuates 
the vasculopathy by triggering vascular wall fibrosis [81]. 
1.1.3. Raynaud’s Phenomenon 
Raynaud‘s Phenomenon (RP) is the clinical manifestation of cutaneous vessel 
dysfunction involved thermal regulation of blood flow [124]. This 
exaggerated respond of the cutaneous circulation to cold exposure results in 
vasospasm and the characteristic pallor of the skin [39]. Its classical 
presentation involves the fingers turning white (ischemia), then blue 
(cyanosis), and then red (reperfusion) [56]. RP presents in almost SSc 
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patients, it is usually the first symptom of disease, and it begins before the 
onset of clinical signs of tissue fibrosis. RP occurs when the delicate balance 
between vasodilation and vasoconstriction is disturbed, in favor of 
vasoconstriction. The presence of RP and dysregulation of cutaneous vascular 
tone is a predictor of developing SSc. The locations of the most severe skin 
fibrosis follow the same distribution patterns as typical cutaneous body sites 
involved in thermoregulation (e.g., the fingers, feet, face, and lower arms), 
suggesting some causative relationship between the vascular disease and skin 
fibrosis. 
Most research into the changes in vascular function in RP has so far focused 
on the endothelium. It has been suggested that RP in SSc patients may be 
triggered by endothelial injury [67] (Figure 1.2). Endothelial activation and/or 
damage will upset the balance between vasodilation and vasoconstriction 
leading to underproduction or reduce efficacy of vasodilators and/or 
overproduction of vasoconstrictors. While the exact mechanism for the initial 
endothelial injury is unknown, apoptosis induced by infection, immumed-
mediated cytoxicity, antiendothelial antibodies, and ischemia-reperfusion 
injury have all been implicated. In addition to the imbalance of vasoactive 
factors, including overproduction of the vasoconstrictor ET-1 and 
underproduction of vasodilator NO and prostacyclin, there is proposing 
evidence of dysregulation of a variety of neurotransmitters and their receptors 
that regulate small sensory nerve fibers as sympathetic vasoconstrictor and 
vasodilator nerves [66]. Decreased release of vasodilatory neuropeptides from 
sensory nerves and up-regulation of vascular smooth muscle α2C-
adrenoreceptors that enhance vasoconstrictive responses to stress or cold 
stimuli are implicated in the dysfunction of the thermoregulatory vessels 
leading to RP. Patients with RP who develop SSc exhibit unique characterized 
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by intimal thickening that can eventually occlude the vessel lumen, thus 
causing ischemic injury and chronic tissue hypoxia (Figure 1.3). Skin hypoxia 
has been documented in SSc patients and is a potent stimulus for growth 
factors that mediate tissue fibrosis [10], suggesting that vascular damage is 
the primary insult, which then provokes tissue fibrosis.  
 
Figure 1.3. Masson‘s trichrome staining of a digital artery from a patient with SSc (A) and 
hematoxylin and eosin staining of a renal artery from a patient of SSc (B). Note of striking 
fibrotic intimal hyperplasia and the adventitial fibrosis in the digital artery and the onion 
skin-like intimal thickening composed of smooth muscle cells and increased connective 
tissue matrix in the renal artery. The intimal hyperplasia results in critical luminal 
narrowing and even occlusion [81]. 
1.1.4. Pulmonary arterial hypertension in systemic sclerosis 
Pulmonary arterial hypertension, defined by an elevated mean pulmonary 
arterial pressure (mPAP) greater than 25 mmHg and a pulmonary capillary 
wedge pressure less than 15 mmHg, is a progressive disorder involving the 
pulmonary vasculature that leads to right heart failure and ultimately death 
[82]. PAH is a serious complication of SSc with prevalence approximately 
15%. SSc- associated PAH (SSc-PAH) is a leading cause of PAH, presents 
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around 15-30% in all PAH. SSc-PAH has a dramatic impact on clinical 
course and overall survival, and remains a major cause of mortality in SSc.  
In the mechanism of SSc-PAH pathogenesis, inflammation is considered as a 
pathological hallmark in which inflammatory cells infiltrate in pulmonary 
perivascular spaces within and around plexiform lesions. On the other hand, 
the role of growth factors such as TGF-β and VEGF in the development of 
SSc-PAH is also indicated in the study of Derrett-Smith et al. [27]. Whether 
this inflammatory process precedes a state of imbalance between vasoactive, 
growth factors and proliferative mediators leading to abnormal regulation of 
endothelial and smooth muscle cells as well as fibroblasts, and vascular 
dysfunction is not elucidated [37]. 
Endothelial dysfunction seems to play an integral role in mediating the 
structural changes in the pulmonary vasculature. Disordered endothelial cell 
proliferation along with concurrent neoangiogenesis, when exuberant, results 
in the formation of glomeruloid structures known as the plexiform lesions, 
which are common pathological features of the pulmonary vessels of patients 
with PAH. Additionally, an altered production of various endothelial 
vasoactive mediators, such as NO, prostacyclin, ET-1, serotonin, and 
thromboxane, has been increasingly recognized in patients with pulmonary 
hypertension. Because most of these mediators affect the growth of the 
smooth muscle cells, an alteration in their production may facilitate the 
development of pulmonary vascular hypertrophy and structural remodeling 
characteristic of pulmonary hypertension. It is conceivable that the beneficial 
effect of many of the treatments currently available for PAH, such as the use 
of prostacyclin, NO, and ET antagonists, result at least in part from restoring 
the balance between these mediators. However, the ultimate cellular and 
physiological targets of these treatments remain unknown [16]. 
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In addition to the potential consequences of an imbalance in the endothelial 
production of various mediators, injury to the endothelium may expose the 
underlying vascular tissue to diverse blood-borne factors that may further 
promote pathological changes. Endothelial dysfunction may also have adverse 
consequences on pulmonary vascular hemostasis by altering the production of 
anticoagulant factors. Recent reports of genetic mutations in the endothelial 
cells of patients with pulmonary hypertension further underscore the role of 
these cells in the disease pathogenesis [16]. 
SSc-PAH shares similar histological features in IPAH, including intimal 
hyperplasia, medial hypertrophy, adventitial fibrosis, and inflammatory 
infiltrates. However, there are fewer plexiform lesions, increased intimal 
fibrosis, more heterogeneity, and a higher prevalence of venoocclusive lesions 
when compared with IPAH [45].   
 
Figure 1.4. Mechanistic role of endothelial dysfunction in pulmonary hypertension and 
pulmonary vascular remodeling. Squares indicate endothelial cells; oval, smooth muscle 
cells; and closed circles, platelets [16]. 
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1.1.5. Collagen deposition 
Fibrosis represents the phenotypic expression (typified by skin thickening and 
interstitial lung fibrosis) of SSc. Patients with the disease have increases in 
collagen types 1 and 3, with type 1 being the most abundant. Type 1 collagen 
is encoded by the COL1A1 and COL1A2 genes, which are at least partly 
controlled by the transcription factor SP1. Increased SP1 binding activity has 
been recorded in sclerodermic fibroblasts and its activity has shown to be 
associated with increased gene expression of type 1 collagen in patients with 
SSc. Gene expression of type 1 collagen is also affected by TGF-β, which 
indicates a possible synergistic profibrotic interaction between SP1 and the 
TGF-β pathway via the SMAD3/4 complexes. Reduced amounts of SMAD7 
(an inhibitor of collagen gene expression) have been reported in SSc, which 
suggests that the loss of this inhibitory effect allows TGF-β to stimulate 
unfettered, excessive accumulation of extracellular matrix.  
1.1.6. Therapeutic targets in systemic sclerosis  
Conventional treatments for SSc 
Among the conventional therapies used for the treatment of SSc (figure 1.5), 
randomized trials have demonstrated a possible effect for methotrexate and 
extracorporeal photopheresis in improving skin thickening, as well as a role 
for cyclophosphamide in stabilizing or even slightly improving interstitial 
lung disease [24, 69]. Calcium channel blocker mostly contribute to the 
management of SSc peripheral vascular disease [117], while angiotensin 
converting enzyme (ACE) inhibitors were proven effective against renal 
impairment [113]. The prostacyclin analogues significantly improved 
pulmonary arterial hypertension associated with SSc [4] as well as peripheral 
vascular disease. The use of D-penicillamine as an antifibrotic agent in SSc is 
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not supported by the results of a randomized trial that compared high to low 
doses of this drug [21]. Other medications and therapeutic procedures such as 
cyclosporine A, sirolimius, tacrolimus, antithymocyte globulin, prazosin, and 
ketanserin have also been used as a therapy for SSc without achieving solid 
evidence of benefits [14]. 
 
Figure 1.5. Summary of the pathogenetic processes leading to fibrosis in SSc and 
mechanism of action of some of the commonly used drugs. PDGF platelet-derived growth 
factor, ET-1 endothelin-1, IL interleukin, TGF-β transforming growth factor-β, CTGF 
connective tissue growth factor, bFGF fibroblast growth factor, ECM extracellular matrix, 
α-SMA alpha-smooth muscle actin, IFN-γ interferon-γ, MTX methotrexate, CYP 
cyclophosphamide, ATG antithymocyte globulin, HSCT hematopoietic stem cell 
transplantation, IVG intravenous gamma globulin, MMF mycophenolate mofetil, CYC A 
cyclosporine A, D-pen D-penicilllamine, PDE-5 phosphodiesterase-5, ACE angiotensine 
converting enzyme, PLTs platelets [14]. 
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Therapeutic target on vascular dysfunction 
As stated previously, endothelial damage and vascular dysfunction could be 
one of the earliest alterations in SSc [107]. The greatest advances have been 
in the management of vascular complications. Angiotensin converting 
enzyme (ACE) inhibitors has been accepted as the preferred choice in 
management of this rapidly fatal complication of SSc. Their mechanism of 
action has been well known (even in the late 1970s) and thought to be 
especially appropriate to treat a hypertensive state that was associated with, 
and driven by, elevated amounts of renin (and thus angiotensin and 
aldosterone) [19]. A review by Steen and colleagues, based on the Pittsburgh 
longitudinal database, records that 1-year survival is better than 70% in renal 
crisis patients treated with ACE inhibitors, but less than 20% in those not 
treated with ACE inhibitors. 
Regarding SSc-associated PAH, some drugs have been approved by US 
Federal Drug Administration (FDA) due to the improved knowledge of 
molecular biology. Epoprostenol, treprostinil, and iloprost can supply 
prostacyclin that the pulmonary vascular endothelium itself no longer supplies 
in adequate quantities; sildenafil can increase amounts of NO in tissue; and 
bosetan can inhibit endothelin, which is overproduced in the serum of patients 
with PAH. These drugs improve the symptoms of PAH as well as the quality 
of life of patients with SSc-associated PAH. Increasing evidence suggests that 
the two treatments that have been approved the longest (epoprostenol and 
bosetan) could improve survival in PAH overall. Several other treatments 
with good molecular-based rationale have been investigated: inhaled 
treprostinil (a prostacyclin-like compound), inhaled nitric oxide, and other 
endothelin inhibitors such as sitaxsentan [46, 83]. Calcium channel blockers 
(especially nifedipine), intravenous iloprost and epoprostenol, and 
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nitroglycerin paste (oilment) are effective in lessening RP and, to a lesser 
extent, in healing digital ulcers. Sildenafil has also shown some effectiveness 
in a small placebo-controlled trial of patients with secondary RP resistant to 
multiple therapies [19]. A study conducted by Sfikakis et al. showed small 
doses of bosentan improve endothelial function without affecting 
hemodynamic parameters or endothelial activation-related processes, thus 
supporting a direct, reversible effect of endothelin in SSc-associated vascular 
injury [110]. 
Iloprost in vasodilator therapies 
The digital arteries of patients with SSc exhibit marked fibrotic intimal 
hyperplasia and luminal narrowing. Normal vasoconstrictor responses to cold, 
superimposed on this anatomic obstruction, could cause occlusion of the 
arterial lumen. Vasodilators that inhibit cold induced vasoconstriction might 
prevent this vessel closure. Alternatively, vasodilator therapies might be 
predicted to be minimally effective in the setting of fixed vascular obstruction 
[29].  
Iloprost is a stable analogue of prostacyclin that is associated with a longer 
duration of vasodilatation [38]. It is widely used for the treatment of vascular 
dysfunction in systemic sclerosis due to its well-known vasodilator and anti-
aggregant effect [36].  
According to the recommendations of the European League against 
Rheumatism (EULAR) for the treatment of systemic sclerosis, iloprost is 
effective in reducing the frequency and severity of SSc-RP. Iloprost, given 
intravenously (0.5–3 ng/kg per minute for 3–5 consecutive days sequentially) 
or orally (50–150 mg twice a day) significantly reduced the frequency of 
ischaemic attacks, and improved the RP severity score in comparison with 
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placebo. Oral prostanoids seem to be generally less effective than intravenous 
iloprost in the treatment of SSc-RP, although some beneficial effects could be 
seen with higher doses. Intravenous prostanoids (particularly intravenous 
iloprost) are efficacious in healing digital ulcers in patients with SSc. 
Intravenous prostanoids (in particular iloprost) should be considered in the 
treatment of active digital ulcers in patients with SSc [71]. 
Iloprost may promote repair of damaged endothelium, which could explain 
vascular effects and clinical improvement weeks after  [29]. Dole et al. 
showed that iloprost can improve healing of cutaneous lesions including 
ischemic ulcers in patients with SSc. The ischemic lesions occur because of a 
vasculopathy characterized histologically by abnormal vascular endothelium 
and intimal thickening, and clinically by vasopasm. The benefit of iloprost on 
tissue healing may in part be explained by the potential capacity of 
prostacyclin to inhibit platelet activation and leukocyte adherence to the 
endothelium thus reducing counteracting defective endothelial function and 
tissue injury [29]. 
1.2. Oxidative stress and systemic sclerosis 
Reactive oxygen species (ROS) is an expanded term from free radicals which 
have been defined as species capable of independent existence that contains 
one or more unpaired electrons in atomic or molecular orbitals [91]. These 
unpaired electrons make free radicals highly reactive in which superoxide 
radical (O2  ˉ), hydrogen peroxide (H2O2), hydroxyl radical (  OH), 
hypochlorous acid (HOCl)  and peroxynitrite (ONOO
-
) are common oxidative 
molecules in the ROS family [87]. With excessive levels, ROS are addressed 
oxidative stress and cause cellular damage and cell transformation.  
Several sources of ROS mentioned to contribute to oxidative stress in fibrotic 
processes of SSc. Ischemia-reperfusion is a main cause leading to tissue 
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damage. In addition, the interaction of cytokines and growth factors with their 
receptors can induce ROS in SSc. Among those, TGF-β is a pivotal 
profibrotic cytokine, which expressed the key role in pathogenesis of SSc. 
Some other significant factors involved are platelet derived growth factors 
(PDGF), vascular endothelial growth factor (VEGF) [12], connective tissue 
growth factor (CTGF), angiotensin II, interleukin 3, interleukin 6, tumor 
necrosis factor-alpha (TNF-α), nerve growth factor, fibroblast growth factor. 
Angiotensin II, PDGF and TGF-β1 can interact with members of the 
nicotinamide adenine dinucleotide phosphate oxidase (NOX) family in 
vascular smooth muscle cells, cardiac, lung and skin fibroblasts [42]. The 
increased level of superoxide from fibroblasts and monocytes also contributes 
to abundant sources of ROS in SSc [30]. 
RP occurring in almost all SSc patients, approximately more than 90% [58],  
presents the oxidative pathway beside the nonoxidative pathway in pathology 
of this phenomenon associated with SSc [51]. There is evidence showing 
induced effects on SSc-associated Raynaud‘s phenomenon. The level of 8-
isoprostane, a reliable biomarker of oxidative stress and antioxidant 
deficiency, has been shown as a valid measure of lipid peroxidation in vivo 
[89]. It is correlated with the extent of vascular lesion in RP and the severity 
of fibrosis in SSc patients [94, 114]. Free radical nitric oxide (NO) released 
by endothelial cells is considered as a beauty in the protective role in 
controlling vasculature and regulating blood pressure as well as acting as 
antithrombotic and cytoprotective agent. However, in RP, during reperfusion, 
free radials and NO produced overwhelmingly lead to peroxynitrate which 
precedes oxidative vascular damage and endothelial apoptosis, therefore NO 
is considered as a beast [17, 51].  
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Figure 1.6. Schematic diagram of ROS-induced fibrotic process in SSc. 
Abundant studies have shown the relevance of ROS in pathogenesis of SSc in 
vitro and in vivo [57, 94, 105, 109]. Oxidative stress is considered as one of 
the main background mechanisms contributing to the progress and destruction 
of this disease, concomitantly clinical manifestations regarding to SSc [51]. 
Skin and visceral fibroblasts spontaneously produce large amounts of ROS 
that initiate collagen synthesis [51]. Recently, a preliminary study of Boin et 
al showed substantially increased intracellular ROS levels in human 
pulmonary artery smooth muscle cells (HPASMCs) treated by sera of SSc 
patients with pulmonary artery hypertension (PAH). Employing NOX2ds-tat 
(gp91ds-tat), a specific inhibitor of NOX2, can effectively reduce PAH-SSc 
sera -induced ROS, implicating the involvement in the mechanism of 
increasing ROS of SSc. Exposure of HPASMCs to SSc-PAH sera also 
resulted in progressive time-related increase of the Collagen promoter 
activity. Similarly, this effect was inhibited by NOX2ds-tat treatment, 
suggesting the collagen synthesis activation in HPAMSCs may be driven by 
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SSc-related PAH sera through NADPH oxidase-dependent ROS generation. 
Taken together, NADPH oxidase-derived ROS mediates the activation of 
collagen synthesis [13]. In vivo studies, exploiting BALB/c mice, the SSc 
murine model injected HOCl every day for 6 weeks induced chronic oxidative 
stress. As a result, this HOCl-induced oxidative stress operated cutaneous and 
lung fibrosis in SSc mice. Furthermore, HOCl-treated mice also 
overexpressed α smooth muscle actin (α-SMA), a biological marker 
characterized by activated myofibroblasts. These processes occurred through 
ADAM17/Notch pathway or Ras-ERK pathway or guanosine triphosphate 
(GTPase) intracellular signaling [5, 6, 68]. Blocking the activation of the Ras-
ERK pathway by propylthiouracil (PTU) or simvastatin can prevent the 
pulmonary fibrosis and cutaneous fibrosis in oxidant-stress animal model of 
SSc [5, 6]. 
Some studies reported that anomalous overproduction of ROS activates 
fibroblasts linking to the increased expression of stimulatory serum 
autoantibodies to the PDGFR in SSc [8]. While prooxidants may cause the 
surging of autoantibodies, other studies showed the uncorrelated relation 
between autoantibodies in endothelial cells and fibroblasts and serum-induced 
ROS or cell proliferation. Nonetheless, it is undeniable the role of 
autoantibodies in the vast damage in SSc in which anti-endothelial cell 
antibodies (AECA) were closely correlated with pulmonary fibrosis with SSc 
[51, 61]. Oxidative stress may either directly activate ROS-induced 
differentiation of fibroblasts into myofibroblasts [68] or disrupt the balance 
between protease and protease inhibitors or both. With the latter mechanism, 
on the one hand, TGF-β upregulates the expression of extracellular matrix 
proteins including collagens, on the other hand, TGF-β suppresses protein 
degradation through enhancing activities of protease inhibitors such as 
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plasmin activator inhibitor 1 (PAI-1) and tissue inhibitors of 
metalloproteinases (TIMPs) [77]. This protease-antiprotease imbalance is 
likely to be a critical mechanism in the development of SSc lung fibrosis [43]. 
1.3. Role of endothelial NADPH oxidases in SSc 
 NOXs are the only enzymes with the primary function of generating ROS 
[31, 73]. Other enzymes (cyclooxygenases, cytochrome P450, enzymes of the 
mitochondrial electron transport chain) can produce ROS, but only as a 
byproduct of their normal function. Of note, these latter enzymes only 
become ROS-generators in the presence of an external source of ROS (such 
as NOXs) and can thus be considered as secondary sources of ROS [32]. 
NOXs catalyze the transfer of electrons from cytosolic NADPH to molecular 
O2 via their membrane-bound catalytic NOX or DUOX subunit to generate 
the ROS, superoxide or H2O2. NOX-derived ROS may promote ROS 
formation from other (normally dormant) enzyme sources, setting up a 
vicious cycle that further exacerbates vascular oxidative stress [78, 86, 92]. 
Accumulative evidence highlights the involvement of NADPH oxidase-
dependent redox signaling in the profibrotic responses mediated by TGF-β 
[104]. 
Seven isoforms of NOX have been described in mammals, each distinguished 
mainly by the identity of its catalytic subunit. They are the ‗NOXs‘: NOX1-, 
NOX2- [formerly gp91phox; also known as CYBB (cytochrome b245, b 
polypeptide)], NOX3-, NOX4-, and NOX5-containing oxidases; and the 
‗DUOXs‘ (‗dual oxidases‘): DUOX1- and DUOX2-containing enzymes. Four 
of the NOXs – NOX1, NOX2, NOX4, and NOX5 – are expressed in 
endothelial cells. 
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Of the four endothelial NOXs, three (NOX1, NOX2, and NOX4) are known 
to exist as multimeric protein complexes, whereby electron transfer occurs 
through the ‗NOX‘ subunit in association with different combinations of 
regulatory subunits. Figure 1.7 illustrates the molecular structures of the 
endothelial NOXs.  
 
Figure 1.7. NADPH oxidase (NOX) isoform expression in the various cell types of the 
blood vessel wall. Four NOX isoforms are expressed in the vascular wall, including NOX1 
(in endothelial cells and vascular smooth-muscle cells, VSMCs), NOX2 (in endothelial 
cells, adventitial fibroblasts, and leukocytes such as monocytes, macrophages, and 
platelets), NOX4 (in endothelial cells, VSMCs, and adventitial fibroblasts), and NOX5 (in 
endothelial and VSMCs – not expressed in rodents) [32]. 
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NOX2 was the first NOX isoform to be identified in endothelial cells and, as 
shall be discussed below, is likely to be the most important in the context of 
vascular pathology.  
NOX4 is the most highly expressed NOX homolog in endothelial cells. It also 
requires p22phox, but apparently does not associate with Rac1 or any of the 
cytosolic organizer or activator proteins needed for activation of NOX1 and 
NOX2 [32]. Current evidence suggests that Nox4 may have a pivotal role in 
mediating TGF-β-induced profibrotic responses [104]. TGF-β increased Nox4 
gene expression without effects on Nox1, Nox2, or Nox5 in human cardiac 
fibroblasts [22]. Treatment with siRNA against Nox4 suppressed expression 
of TGF-β target genes including fibronectin, collagen I, α-smooth muscle 
actin (α-SMA, a marker of myofibroblast), and connective tissue growth 
factor, indicating that Nox4 was involved in TGF-β-induced differentiation of 
cardiac fibroblasts to myofibroblasts [22]. In renal tubular epithelial cells, 
Rhyu et al. showed that inhibition of NADPH oxidase activity with the non-
selective Nox inhibitor DPI suppressed EMT and matrix protein production 
[100]. 
NOX5 appears to be the only endothelial NOX that can produce ROS in the 
absence of other ‗phox‘ or Rac subunits. NOX5 is also unique among NOX 
isoforms in that it contains an N-terminal calmodulin-like domain with four 
binding sites for Ca
2+
 (EF hands). Thus, endothelial NOX5 activity can be 
directly modulated by changes in intracellular [Ca
2+
] [9].  
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Figure 1.8. Molecular composition of the endothelial NADPH oxidases (‗NOXs‘). All four 
endothelial NOX isoforms are comprised of a catalytic ‗NOX‘ subunit, which may reside 
in the nuclear, endoplasmic reticulum (ER), or plasma membranes. For NOX1, 2, and 4, 
additional subunits are required for full enzyme activity. By contrast, NOX5 is a ―stand 
alone‖ protein whose activity is regulated by Ca2+ binding. The topology of the NOXs is 
such that NADPH binds to the cytoplasmic domains of the proteins with reactive oxygen 
species (ROS) generation always occurring on the opposite side of the membrane (i.e., 
within the nucleus, ER, or the extracellular compartment). It is also noteworthy that 
whereas NOX1, 2, and 5 generate superoxide, NOX4 appears to generate hydrogen 
peroxide [32]. 
1.4. Endothelial-to-Mesenchymal Transition and Systemic Sclerosis 
Pathogenesis of systemic sclerosis constitutes numerous complex mechanisms 
associated with (i) microvascular fibroproliferative lesions, (ii) innate and 
adaptive immune system abnormalities and uncontrolled accumulation of 
collagen, (iii) other extracellular matrix compartments produced by 
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fibroblasts and activated myofibroblasts in skin and various internal organ 
[64, 95]. In a non-pathological condition, myofibroblasts usually disappear 
through apoptosis and through transition to a quiescent/senescent state at the 
later stages of wound healing. However, the persistence of myofibroblasts 
under an activated phenotype in EndMT contributes to progressive 
fibrogenesis [90, 111]. The consequence of this process is causing interstitial 
and perivascular fibrosis in the lungs, heart, kidneys and other organs 
responsible for the high mortality of SSc patients [11]. The origin of activated 
myofibroblasts in SSc has been demonstrated from various sources including 
pericytes and smooth muscle cells (SMCs) from vessel walls, resident 
fibroblasts, bone marrow-derived fibroblasts [60, 64, 126]. With large 
amounts of studies, Epithelial-to-Mesenchymal Transition is a well-known 
source of activated myofibroblasts by which epithelial cells transforms into 
myofibroblasts. Although it is not extensively studied as EMT, more recent 
research has been conducted to investigate the mediators and signaling 
pathways in mechanisms of differentiation of endothelial cells to 
mesenchymal transition. EndMT is considered as a special form of EMT, 
vascular endothelial cells share several similar characteristics and molecular 
mechanisms with epithelial cells to generate fibroblasts and myofibroblasts 
[74, 99]. EndMT contributes to fibrotic pathogenesis of cardiac fibrosis, 
pulmonary fibrosis, renal fibrosis, idiopathic portal hypertension, liver 
fibrosis, and obviously systemic sclerosis [54, 64, 106, 115, 127].  
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Figure 1.9. Multiple origins of myofibroblasts [126]. 
Under the conversion of endothelium into mesenchyme, endothelial cells 
undergo morphological alterations and loss of cell-surface markers. In cell 
culture, endothelium acquires mesenchymal, fibroblast-like properties such as 
spindle-shaped morphology, migratory capacity, invasiveness, and enhanced 
resistance of apoptosis [60, 120]. During EndMT process, the structure of 
vessel-lining is disrupted due to resident endothelial cells disaggregating from 
the organized layer of cells on vessel walls and invading the surrounding 
tissue [76, 97, 120]. Cell-surface markers like vascular endothelial cadherin 
(VE-Cadherin), CD31 (platelet endothelial cell adhesion molecule-1, PECAM 
1) or von Willebrand factor (vWF) are gradually replaced by markers 
characterized for mesenchyme such as fibroblast specific protein-1 (FSP-1), 
α-SMA, vimentin and type I and type III collagen [54, 97].  
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Figure 1.10. Endothelial-to-Mesenchymal Transition. Endothelial cells can 
transdifferentiate into fibroblasts under the influence of several factors. This transition is 
accompanied by the progressive loss of typical endothelial cell markers (VE-cadherin, 
vWF, CD31) and the transcription of typical mesenchymal cell markers (FSP-1, MMP-2, 
MMP-9, vimentin, α-SMA, collagen I). This process can be reverted by the administration 
of BMP-7 or HGF. Under the effect of variety of mediators, fibroblasts differentiate into 
myofibroblasts which leads to ECM and collagen synthesis [102]. 
Studies demonstrated the presence of transitional EndMT cells in the 
pulmonary vasculature of patients with SSc-PAH. The expression of cell 
surface markers specific for  endothelial cells in mesenchymal/fibroblastic cells 
or vice versa from SSc-PAH patients [48, 97]. Treatment of IL-1β, TNF-α and 
TGF-β in combination abolished cobblestone structural characteristics and 
enhanced spindle-like appearance on pulmonary artery endothelial cells. 
Induced endothelial-mesenchymal transition (I-EndMT) cells exhibit an 
elevated secretion of proinflammatory proteins and collagen type I. In addition, 
the presence of I-EndMT cells in cellular barriers leads to substantially 
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increased paracellular and transcellular permeability which is considered as one 
of the earliest  signs of vascular dysfunction in SSc [43, 48].  
The mechanism of EndMT in pathogenesis of SSc vasculopathy is postulated 
to be induced by synergistic and complex activation of a large variety of cell 
types exposing to locally various biological mediators, such as inflammatory 
cytokines, growth factors [54, 95]. However, the precise molecular 
mechanisms of EndMT process mediated by those mediators and signaling 
pathways have not been entirely illuminated. Among these mediators, TGF-β 
has been implicated as a key role in the initiation of EndMT by numerous 
evidence [23, 49, 64, 90, 97, 120].  
TGF-β can either solely activate endothelial cells or synergize with TNF-α 
and IL-1β to induce EndMT. Maleszewska et al (2013) demonstrated that the 
treatment with either TGF-β2 or IL-1β resulted in alterations of endothelial 
cells morphology, followed by a spindle-shaped phenotype. Nevertheless, 
under a co-stimulation condition the morphological changes were more 
explicit than in the case of single-factor stimulation [79]. Similarly, Good et al 
(2015) showed evidence that a combination of TGF-β with IL-1β and TNF-α 
stimulated the induction of EndMT in pulmonary artery endothelial cells. 
Notably, the withdrawal of IL-1β, TNF-α, and TGF-β after 6 days failed to 
convert induced EndMT (I-EndMT) cells to normal structural characteristic. It 
indicated that phenotypic change was permanent and was not reversible [48, 
99]. This observation was in agreement with previous studies that EndMT 
would be consistent in the cells exposed to activated Ras and TGF-β 
treatment [53]. However, other reports showed that some anti-fibrotic 
mediators could dedifferentiate established myofibroblasts. This raises 
enormous hope for regenerative medicine in the reversal of the EndMT 
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process, which provides a new intriguing therapeutic target for fibrotic 
diseases [44, 126]. 
There are some signaling pathways involved in EndMT in which TGF-β plays 
a critical role. Both Smad-dependent and Smad-independent pathways are 
associated in intracellular cascades activated by TGF-β during endothelial-
mesenchymal transition. Smad proteins have been shown to bind directly to 
the promoter of the Snail gene to regulate its transcription [23] . Snail-1, a 
transcriptional repressor, is crucial for TGF-β-induced mesenchymal 
transdifferentiation of embryonic stem cell-derived ECs. Snail-1 is a zinc-
finger transcription factor that forms a complex with Smad3/Smad4. The 
active Smad3/Smad4/Snail-1 complex results in potent inhibition of the 
expression of E-cadherin by directly integrating into specific sequences 
within the gene promoter and blocking its transcription. In addition to 
inhibition of E-cadherin, Snail-1 precedes transcriptional events that lead to 
the expression of a mesenchymal-cell-specific phenotype [64]. In the Smad-
independent pathway of TGF-β signaling, there is an involvement of 
important kinases such as c-Abl protein kinase (c-Abl), protein kinase Cδ 
(PKC-δ), and glycogen synthase kinase 3β (GSK-3β). GSK-3β is a crucial 
factor, whose phosphorylation will cause its inhibition and induce the strong 
up-regulation and subsequent translocation of Snail-1 into the nuclear. In the 
end, this process increases the expression of mesenchymal cell-specific 
marker such as α-SMA, type I collagen while reduce the expression of VE-
cadherin characterized for endothelial cells. Using inhibitors of c-Abl and 
PKC-δ, imatinib and rottlerin respectively can inhibit the phosphorylation of 
GSK-3β, hence; abolish the transdifferentiation of ECs into myofibroblasts. 
This intervention could be a potential therapeutic target to obliterate the 
acquisition of the myofibroblastic phenotype through EndMT process [75]. 
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TGF-β2 signals through MEK, PI3K, and p38MAPK pathways are also 
essential for ECs undergoing EndMT transition [84]. In addition, regulation of 
EndMT by Wnt [123] and NOTCH signaling [93], Caveolin-1 signaling [25, 
26] is indicated to precede endothelial-mesenchymal transition regarding to 
TGF-β activity.  
Other cytokines and growth factors might also play important roles in 
endothelial-mesenchymal transition such as PDGF, VEGF, endothelial-1 (ET-
1), CTGF, MicroRNAs (miRNAs) [64].  
1.5. Reactive oxygen species and Endothelial-to-Mesenchymal Transition 
With numerous profound studies of the effects of oxidative stress on 
endothelial dysfunction, ROS have been highlighted in the process of 
epithelial-mesenchymal conversion [88]. Previous reports have demonstrated 
that EMT is closely relevant to ROS [74]. Recently, it has been reported that 
oxidative stress induces the EMT in renal tubular epithelial cells, human 
epithelial keratinocytes, and lung epithelial cells [28, 40, 101]. An emerging 
issue is whether there is a similar tendency towards EndMT.  
1.5.1. ROS activate/mediate TGF-β-dependent signaling pathways in 
EndMT. 
TGF-β is a multifunctional protein including three isoforms (TGF-β1, TGF-
β2, and TGF-β3) which accounts for the regulation of cell proliferation, 
differentiation, apoptosis, adhesion, and migration. It therefore shows 
profound systemic effects on physiological functions [63, 77]. TGF-β 
stimulates the generation of ROS in various types of cells while ROS activate 
TGF-β and mediate effects of TGF-β. TGF-β elevates ROS production via 
NOX4, mitochondria, and microsomes. On the other hand, ROS induce TGF-
β gene expression and activate TGF-β through oxidizing latency association 
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protein (LAP) or activating MMPs, which in turn release LAP [77].  It is well 
known that TGF-β is synthesized as a non-active pro-form combining with 
latency association protein (LAP) to create a latent complex. ROS oxidizing 
Redox center of LAP can trigger a conformational change resulting to the 
release of TGF-β1 [65]. Hence, under the stimulation of ROS, TGF-β is 
activated and increasingly expressed.  
 It is well documented that TGF-β induced EndMT process in cardiac, 
pulmonary fibrosis, renal, intestinal and skin fibrosis [20, 53, 54, 103, 127] 
whereas NADPH oxidases and ROS molecules may have been indicated to 
play a pivotal role in mediating TGF-β induced fibrotic responses via 
Smad2/Smad 3 activation [63]. Of note, NOX4-dependent generation of H2O2 
is required for TGF-β1-induced myofibroblasts differentiation and elevated 
ECM production [55, 62]. 
A recent study of Montorfano group used human umbilical vein endothelial 
cells (HUVECs) to investigate the role of ROS as well as the underlying 
mechanism in the conversion of ECs into myofibroblasts. They demonstrated 
that oxidative stress is a crucial factor in generating the phenotypic 
conversion of ECs into activated myofibroblasts with an EndMT-like 
mechanism via a TGF-β1 and TGF-β2-dependent pathway. In addition, this 
study showed that ROS-induced oxidative stress acted on the conversion 
through the ALK5/Smad3/NF-кB intracellular pathway. The main point of 
this study supporting the hypothesis that ROS, TGF-β and EndMT is in an 
interactional relation is H2O2 induced the expression and secretion of  TGF-β1 
and TGF-β2, which has been demonstrated to induce the conversion of ECs 
into myofibroblasts [87]. Another recent study provided evidence that 
lipopolysaccharide-induced ROS could lead to an EndMT-like process 
through an ALK5 activity-dependent mechanism [33]. In line with this 
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observation, Toshio group (2015) also showed  novel evidence that 
endotoxaemia-derived oxidative stress might be one of the promoters of TGF-
β-mediated EndMT in pulmonary vascular endothelial cells [118]. This 
evidence was strongly supported with the newer study by the same authors 
that the expression of TGF-β1 and TGF-β2 is crucial for the development of 
the endotoxin-induced endothelial fibrosis mechanism. This increase of 
endotoxin-induced TGF-β1 and TGF-β2 expression required the activation of 
NOX and the subsequent generation of ROS [34]. Taken together, oxidative 
stress is likely a link to mediate the EndMT process induced by TGF-β.  
1.5.2. Oxidative stress and EndMT in SSc: is there a link? 
Despite the fact that the role of ROS has been well defined in many interstitial 
organ fibrosis as well as strong there being strong evidences displaying the 
close relationships between ROS and SSc, EndMT and SSc (stated above) via 
numerous relevant papers, few studies have conducted experimental research 
indicating the effects of oxidative stress on EndMT process in SSc. A study 
conducted by Hao Xu group showed chronic oxidative stress mediates 
Endothelial-to-Mesenchymal Transition in a murine model of SSc [125]. 
They isolated microfibrils from the skin of tight skin (Tsk
+/-
) mice, which 
showed abnormal big fibrillin-1. EC cultures on this abnormal extracellular 
matrix leaded to the alterations of morphology and function of ECs, and 
increased 4-HNE, a well-known fission product of polyunsaturated fatty acid 
oxidation. There was a transdifferentiation from ECs to mesenchymal cells 
with the increased presence of FSP-1 and Twist (a transcription factor 
implicated the endothelial cell to fibroblast transition) and a decrease of VE-
cadherin. Beside, abnormal big fibrillin expression was associated with 
oxidative stress (reduced nitric-oxide-to-superoxide anion ratio). This 
suggested an oxidative involvement in the transition. In addition, pretreatment 
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D-4F, a peptide binding with high affinity to oxidized lipids attenuated or 
abolished EndMT. This indicated that the oxidized lipids might play a central 
role in the mechanisms by which other chronic states of oxidative stress 
promotes endothelial mesenchymal transition [125]. In this paper, the authors 
did not mention TGF-β, which has been well documented to be a crucial role 
in the initiation of EndMT during various diseases [64]. Of note, ECM 
including fibrillin functions as a reservoir for TGF-β and other growth factors 
to control mesenchymal differentiation [121]. Whether there is an interaction 
between TGF-β and oxidative stress to precede EndMT in this case is an 
intriguing question, which requires more investigation to figure out.  
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2. RESEARCH OBJECTIVES 
Systemic sclerosis (scleroderma, SSc) is a complex multisystem autoimmune 
disease characterized by dysregulated immune system, progressive fibrosis of 
skin and visceral organs in which extensive vascular alterations are prominent 
and severe [41].  
Despite of the enormous scientific effort in studying etiology and 
pathogenesis of scleroderma, an overall picture of its etiopathogenic 
mechanisms remains obscure. Oxidative stress-mediated vascular dysfunction 
is one of the important features of the detrimental vascular changes in SSc 
patients. Although the presence of a large excess of ROS has been supported 
by numerous studies, which documented the aberrant redox state and 
demonstrated the involvement of ROS in excessive extracellular matrix 
deposition, the implication of molecular machinery is still unclear [42]. Many 
clinical trials with antioxidants have been undertaken to inhibit the 
progression of SSc.  
Iloprost, a stable prostacyclin analogue with vasodilating, anti-platelet, 
cytoprotective and immunomodulating properties, has been found to be an 
efficacious alternative to nifedipine for the treatment of SSc [108]. Some 
studies reported that iloprost infusion reduces oxidative stress and improves 
fibrosis in SSc patients [36, 108, 116]. However, the mechanism underlying 
this beneficial effect remains unelucidated.  
Aside from Epithelial-to-Mesenchymal Transition (EMT), which has been 
extensively shown to occur in a variety of fibrotic diseases including SSc [18, 
54, 70, 115], a potential role of Endothelial-to-Mesenchymal Transition 
(EndMT) in scleroderma has been indicated in some reports. EndMT may 
trigger the enhanced fibroproliferative vasculopathy and is considered as a 
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novel mechanism for the generation of activated myofibroblasts in SSc [64]. 
Consonant to what reported above, ROS mediate TGF-β-induced 
differentiation of myofibroblasts, which accounts for the increased production 
of fibrillar type I and type III collagen and other extracellular matrix (ECM) 
proteins, and triggers the expression of α-smooth muscle actin (α-SMA), a 
process strongly correlated EndMT [22, 64].  
The research question of this study was to understand whether oxidative stress 
and EndMT could be part of the molecular machinery inducing vascular 
damage in SSc patients.  
Therefore, we have been conducting this study with the following intents:  
1. To investigate whether SSc sera can induce oxidative stress and collagen 
synthesis in HPMECs. 
2. To examine the effect of intravenous iloprost infusion on SSc sera and how 
this alteration affects in HPMECs.  
3. To investigate whether SSc sera can induce Endothelial-to-Mesenchymal 
Transition in HPMECs. 
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3. MATERIALS AND METHODS 
3.1. Ethical approval 
The study was approved by the Ethics Committee, from both the University 
of Sassari and the John Hopkins University, Baltimore (USA), and all patients 
enrolled were  informed consent. 
3.2. Patient selection 
Serum samples were collected from patients with SSc at the Johns Hopkins 
Scleroderma Center, Division of Rheumatology, Johns Hopkins University, 
Baltimore, and at the Unit of Complex Rheumatology, Sassari. In Baltimore, 
nineteen patients were enrolled in the study. In Sassari, sixteen patients were 
enrolled in the study. The clinical and serological characteristics of these SSc 
patients in Baltimore and Sassari are summarized in table 4.1 and table 4.2, 
respectively. 
All the patients with SSc had to fulfill the American College of 
Rheumatology (formerly, the American Rheumatism Association)-SSc 
classification criteria. Using these guidelines, patients with skin sclerosis 
limited to hands, forearms, legs below the knee, and face were defined as 
having limited scleroderma. Those with more extensive skin disease 
spreading proximal to elbows or knees or involving the trunk were defined as 
having diffuse scleroderma. The onset of the disease was defined as the time 
of the first non-Raynaud phenomenon.  
The SSc patients from Sassari underwent a monthly intravenous 
administration by an infusion pump of the prostacyclin analogue iloprost, at 
the greatest tolerated dose (0.5-2 ng/kg/min, mean dose 1.3 ng/kg/min), for 5-
6 hours/day. Blood samples were taken at two different time points. For each 
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patient, blood samples were  taken at baseline and 5 hours after the cycle of 
iloprost infusion. Samples were stored at -80
0
C until being assayed.  
Previous medications were maintained during the course of the study; no 
other drugs were started during the study period. 
Healthy donors were matched for gender, race, and smoking status. 
3.3. Cells and Chemicals 
Human pulmonary microvascular endothelial cells (HPMECs) were supplied 
by Innoprot, S.L, Spain.  
Primary antibodies Rabbit polyclonal IgG anti-von Willebrand (Santa Cruz 
Biotechnology, INC); Goat Polyclonal Anti-Actin Alpha 2 Smooth Muscle 
Antibody (Novus Biologicals); β-actin antibody from Sigma-Aldrich (Saint-
Louis, MO, USA); the HRP-conjugated secondary antibodies were from 
Santa Cruz Biotechnology, INC and Pierce Biotechnology-Thermo Scientific 
(Rockford, USA). 
3.4. Cell culture 
Human pulmonary microvascular endothelial cells (HPMECs) were cultured 
in endothelial cell medium (ECM) (Innoprot, S.L, Spain) supplemented with 
5% of Fetal Bovine Serum (FBS), 1% of Endothelial Cell Growth Supplement 
(ECGS), and 1% of Penicillin/Streptomycin solution (P/S solution). The cells 
were maintained at 37
0
C and 5% CO2 in a humid environment. 
3.5. Measurement of intracellular ROS  
Intracellular ROS levels were determined by using the ROS molecular probe 
2‘, 7‘-dichlorodihydrofluorescein diacetate (H2-DCFDA) (Molecular Probe, 
Eugene, OP) as previously described with minor modification. Within the 
cell, esterases cleave the acetate groups on H2-DCFDA, thus trapping the 
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reduced form of the probe (H2-DCF). Intracellular ROS oxidize H2DCF, 
yielding the fluorescent product, DCF. 
HPMECs (10
5
 cells per well) were seeded in black 96-well plates (Costar, 
Corning, Inc, NY) and incubated with their respective growth medium alone 
for 24 hours at 37
0
C with an atmosphere of 5% CO2/95% air. Culture media 
were then removed and cells were pre-incubated for 15 minutes with Earle‘s 
balanced salt solution (Sigma, MO, USA) containing 10 µM H2-DCFDA, and 
then washed with PBS. After 15 minutes, cells were treated with sera (10% 
V/V) of SSc and HD. Fluorescence was measured by using a Tecan GENios 
plus microplate reader (Tecan, Mannedorf) in a light protected condition for 5 
hours. Excitation and emission wavelengths used for fluorescence 
quantification were 485 nm and 535 nm respectively.   
3.6. Measurement of intracellular ROS with NADPH inhibitors 
HPMECs (10
5
 cells per well) were seeded in black 96-well plates (Costar, 
Corning, Inc, NY) and incubated with their respective growth medium alone 
for 24 hours at 37
0
C with an atmosphere of 5% CO2/95% air. Cells were pre-
treated with a broad NOX inhibitor, diphenylene iodonium (DPI) 5µM for 
one hour or with a specific NOX2 inhibitor, gp91ds-tat 5µM for one hour. 
Culture media were then removed and cells were pre-incubated for 15 
minutes with Earle‘s balanced salt solution (Sigma, MO, USA) containing 10 
µM H2-DCFDA, and then washed with PBS. Subsequently, cells were treated 
with sera (10% V/V) of SSc and HD. Fluorescence was measured by using a 
Tecan GENios plus microplate reader (Tecan, Männedorf) in a light protected 
condition for 5 hours. Excitation and emission wavelengths used for 
fluorescence quantification were 485 nm and 535 nm respectively.  
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3.7. Molecular cloning and production of lentiviral particles  
In this study we have used p47-roGFP, a redox biosensor that allows for 
noninvasive quantitative imaging of NADPH oxidase activity and 
pCOL1A1LV-tGFP, a human α(1) procollagen promoter to evaluate the 
activity of collagen synthesis in cells.   
3.7.1. Cloning of the p47-roGFP biosensor construct 
The coding sequences of human p47phox and roGFP2 were amplified by PCR 
from plasmid pcDNA3.1-p47-roGFP (kindly provided from Prof. George G. 
Rodney). XbaI and SalI restriction sites (underlined in primer sequence) were 
added to the forward (5‘CGCTCTAGAATGGGGGACACCTTCATCCGT-3‘) 
and reverse (5‘AGTCGACACTTACTTGTACAGCTCGTCCATG-3‘) primers, 
respectively. The PCR product was purified and cloned into the lentivector 
p156CMVGFP (kindly provided from Prof. Franco Galimi) using XbaI and 
Sal I restriction sites. The final construct has been checked by sequentiation. 
 
Figure 3.1. Construction of the Nox biosensor p47-roGFP. 
3.7.2. Cloning of Human A(I) procollagen gene promoter  
Human α(I) procollagen promoter (from -804 to +42) was cloned into a pJ241 
plasmid using SalI and PmeI restriction sites. Then, the insert with Human 
α(I) procollagen promoter (from -804 to +42) was cut with SalI and PmeI 
restriction enzymes and subcloned into a lentivector containing tGFP protein. 
The final viral construct has been checked by sequentiation. 
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Figure 3.2. Human α(I) procollagen gene promoter-Lentivector-tGFP..  
3.7.3. HPMEC transduction 
Day0: In the T25 flasks, seed the HPMECs in Endothelial Cell Medium 
(ECM) (Innoprot, S.L, Spain) supplemented with 5% of FBS, 1% of ECGS, 
and 1% of P/S solution at appropriate density and incubate overnight (50%-
75% confluent). 
Day1: Remove the culture medium; add 1.5 mL of ECM complete medium to 
cover the surface of cell culture. Thaw the lentiviral stock at room 
temperature. Add appropriate amount of virus stock. Return cells to 37ºC/CO2 
incubator.  
Day2: The day after, add ECM complete medium to reach 5 mL of volume. 
Day3-4: At around 48-72h (depend on the protein) after transduction, check 
the protein production using fluorescence microscopy. 
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3.8. Determination of NOX2-associated ROS using NOX-specific redox 
biosensor p47-roGFP 
Determination of NOX2-associated ROS was investigated by using the NOX-
specific redox biosensor p47-redox-sensing green fluorescent protein (p47-
roGFP). P47-roGFP, which was kindly provided from Prof. George G. 
Rodney, is a fusion of p47
phox
, a subunit of NADPH oxidase 2 and roGFP2. 
P47-roGFP has two fluorescence excitation maxima at 400 (oxidized form) 
and 485 nm (reduced form) and display rapid and reversible ratiometric 
changes in fluorescence in response to changes in ambient redox potential. 
The ratios of fluorescence from excitation at 400 and 485 nm indicate the 
extent of oxidation and thus the redox potential while canceling out the 
amount of indicator and the absolute optical sensitivity. Fluorescence 
measurements were performed in black 96-well plates (Costar, Corning, Inc, 
NY) on a fluorescence microplate reader GENios plus (Tecan, Männedorf, 
CH). Cells were excited by using 400 and 485 nm filters and fluorescence 
values were measured using 535 nm emission filter. These values were 
averaged and subtracted from the fluorescence values of roGFP.  
HPMECs transduced with p47-roGFP lentiviral particles (10
5
 cells/mL) were 
seeded in black 96-well microplate (Costar, Corning, Inc, NY). Sub-confluent 
cells then cultured in basal medium containing 10% (V/V) of sera from SSc 
and HD subjects. Variations of redox status were kinetically followed for 5 
hours and values at 2 hours were used for comparison.  
3.9. Measurement of collagen promoter activity 
Collagen promoter activity was investigated by employing pCOL1A1-LV-
tGFP (Innoprot, S.L, Spain), a green fluorescence protein-based lentiviral 
vector transduced into the cells. This gene is driven by the human COL1A1 
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gene promoter. A red fluorescence was used to normalize the cell transduction 
efficiency. Fluorescence measurements were performed in black 96-well 
plates (Costar, Corning, Inc, NY) on a fluorescence plate reader GENios plus 
(Tecan, Männedorf, CH). Cells were excited by using 485 and 535 nm filters 
and fluorescence values were measured using 535 and 590 nm emission filter 
for pCOL1A1-LV-tGFP and EFα-LV-FP602, respectively.  
HPMECs were transduced with lentiviral particles, which were obtained from 
the pCOL1A1-LV-tGFP and EFα-LV-FP602 lentivectors, and then cultured in 
basal medium containing 10% (V/V) of sera from SSc and HD subjects. 
Variations of COL1A promoter activation were kinetically followed for 48 
hours. Data are normalized for transduction efficiency by reporting the ratio of 
pCOL1A1-LV-tGFP to EFα-LV-FP602 Relative Fluorescence Units (RFU). 
3.10. Cell proliferation assay (BrdU incorporation Assay) 
Cell proliferation was assessed by using chemiluminescent immunoassay, 
which based on the measurement of BrdU incorporation during DNA 
synthesis. When cells are pulsed with BrdU, it is incorporated into newly 
synthesized DNA strands of actively proliferating cells. The incorporation of 
BrdU into cellular DNA may then be detected using anti-BrdU antibodies, 
allowing assessment of the population of cells, which are synthesizing DNA. 
The assay was performed in a black 96-well plate using a commercially 
available kit (ROCHE). 5x10
3
 cells per well were seeded in black 96-well 
plates and were cultured with M199 medium plus 2.5% FBS overnight. BrdU 
was added in each well of microplate, followed by incubation for 10 hours. 
Subsequently, supernatant was removed and was fixed by Fix-Denat solution 
for 30 minutes. Then, Fix-Denat was discarded and cells were incubated with 
an anti-BrdU antibody conjugated to peroxidase (anti-BrdU-POD) for 90 
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minutes. After rising three times with washing buffer, substrate solution was 
added and allowed to react for 3 minutes at room temperature. Finally, light 
emission was read by using a GENios plus microplate reader (Tecan, 
Mannedorf, CH). Results were expressed as mean ± SD. 
3.11. Protein extraction  
Cells were cultured in T12.5 culture flasks (BD Falcon). Sub-confluent 
HPMECs were treated with 10% (V/V) of sera of SSc patients and healthy 
donors for 72 hours. After 72-hour treatment, flasks were harvested and 
washed with chilled PBS. The cells were then incubated in ice-cold lysis 
buffer (CytoBuster protein extraction reagent; Novagen, Darmstadt, 
Germany) with freshly added protease inhibitor cocktails (Protease Inhibitor 
Cocktail and Phosphatase Inhibitor Cocktail 2, 3; Sigma, St Louis, MO) over 
ice for 10 min. The cell debris was scraped; the lysate was collected in a 
microfuge tube and cleared by centrifugation at 16,000g for 5 min at 4
0
 C.  
Supernatants were collected and stored in the same lysis buffer and stored at 
minus 80
0
C. The protein content in the lysates was measured by Bradford 
assay following the manufacturer‘s protocol (Sigma, St Louis, MO). 
3.12. Western Blotting 
Protein extract and supernatant were subjected to SDS polyacrylamide gel 
electrophoresis (SDS-PAGE), and resolved proteins were transferred to a 
nitrocellulose membrane. The non-specific sites were blocked with blocking 
buffer (TBS containing 5% BSA and 0.1% Tween-20) for 2 hours on a rocker 
at room temperature. The blocked membrane was washed with washing 
buffer (TBS containing 0.1% Tween-20) three times (5 min) and then 
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We used specific antibodies against von Willebrand factor protein vWF 
(Santa Cruz Biotechnology, INC), alpha-smooth muscle actin α-SMA (Novus 
Biologicals); and β-actin (Sigma-Aldrich, Saint-Louis, MO, USA). 
The day after, the membrane was thoroughly washed with TBS/Tween, and 
incubated with a secondary antibody for one hour on the rocker at room 
temperature. Bands were detected using a peroxidase-conjugated IgG 
antibody and visualized by enhanced chemiluminescence. Beta actin was used 
as a loading control. 
Protein content was determined by densitometric scanning of immunoreactive 
bands (Versadoc Imaging System; Bio-Rad). Results were expressed as 
arbitrary units, and ratios of individual densitometric results were normalized 
to β-actin immunoreactivity. 
3.13. Statistical analysis 
Data are shown for individual subjects in absolute values and presented as as 
mean ± SD. One or two way repeated measurement ANOVA followed by the 
Sidak‘s test was used to detect differences between more than two groups. 
Differences were considered to be statistically significant at p < 0.05.  
Statistical analysis was performed using GraphPad Prism 6.00 for Windows 
(GraphPad Software, San Diego, CA). 
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4. RESULTS 
 
4.1. Clinical and serological characteristics of SSc patients. 
SSc patients from Baltimore enrolled in the study were mainly middle age, 
white women. Subjects with SSc were slightly older than healthy donors (64.0 
± 9.4 vs 54.1 ±10.4; p = 0.0075). 
Table 4.1. Clinical characterization of SSc patients in Baltimore 
 SSc patients 
(n = 19) 
Healthy donors 
(n = 14) 
p 
value 
Sex, female/male 16/3 12/2  
Age, median (range) years 64.0 ± 9.4 54.1 ± 10.4 0.0075 
Race (white/black) 16/3 11/3  
Disease duration 21.7 ± 9.4   
SSc types (diffuse/limited) 3/16   
Autoantibodies 
Anti  RNA polymerase 3 
Anti  Scl -70 






Medication use (current) 
       Immunosuppressants 
       Calcium channel blocker 
       Endothelin receptor antagonist 
       Phosphodiesterase 5 inhibitor 
       Prostanoid 
       Statin 
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Similarly, SSc patients from Sassari enrolled in the study were mainly middle 
age, white women. Subjects with SSc were not significantly different 
compared healthy donors (p = 0.8203)  
Table 4.2. Clinical characterization of SSc patients in Sassari 
 SSc patients 
(n = 16) 
Healthy donors 
(n = 14) 
p 
value 
Sex, female/male 12/4 12/2  
Age, median (range) years 55 ± 11 54.1 ± 10.4 0.8203 
Race (white/black) 15/1 11/3  
Disease duration, mean ± SD 13 ± 12.3   
SSc types (diffuse/limited) 11/5   
Autoantibodies 
Anti  RNA polymerase 3 
Anti  Scl -70 






Medication use (current) 
       Immunosuppressants 
       Calcium channel blocker 
       Endothelin receptor antagonist 
       Phosphodiesterase 5 inhibitor 
       Prostanoid 
       Statin 
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4.2. Sera of patients with SSc increased intracellular ROS level in 
HPMECs  
We first tested whether sera of SSc patients could elicit a rise on intracellular 
ROS levels. Before stimulation, sub-confluent HPMECs were loaded with 10 
µM H2 -DCFDA and then cultured in basal medium containing 10% (V/V) of 
sera from SSc patients and HD. Variations in intracellular ROS levels were 
kinetically determined in a 5-hour time-course experiment (Figure 4.1 A) and 
values at two hours, which show the maximum values, were used for 
comparison. As reported in the graphs, SSc sera significantly increased 
intracellular ROS levels in HPMECs.  
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(A)       (B) 
Figure 4.1. Effect of SSc sera on HPMEC production of intracellular ROS levels. 
Before stimulation, sub-confluent HPMECs were loaded with 10 µM H2 -DCFDA and then 
cultured in basal medium containing 10% (V/V) of sera from SSc patients and HD. 
Variations in intracellular ROS levels were kinetically determined in a 5-hour time-course 
experiment (Figure 4.1 A) and values at 2 hours were used for comparison (Figure 4.1 B). 
Fluorescence data were expressed as Relative Fluorescence Units (RFU). * p < 0.05: 
significantly different from control group (HD). 
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4.3. DPI reduced intracellular ROS levels induced by sera of SSc patient. 
In tra c e llu la r  R O S
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Figure 4.2. Diphenylene iodonium (DPI), a broad NOX inhibitor was exploited to 
investigate potential association between NOX family and the sera-induced ROS. 
HPMECs were treated with DPI 5µM for 1 hour, subsequently with 10% (V/V) of sera 
from SSc patients and HD. Variations in intracellular ROS levels were kinetically 
determined in a 6-hour time-course experiment. Fluorescence data were expressed as 
Relative Fluorescence Units (RFU).  
Among the most important ligand-mediated sources of intracellular ROS are 
NADPH (NOX) oxidases. We therefore investigated the potential 
involvement of NADPH oxidases (NOX) in the increase of ROS elicited by 
sera of SSc patients. Diphenylene iodonium (DPI), a broad NOX inhibitor 
was exploited to investigate the association between NOX family and SSc 
sera-induced ROS generation. HPMECs were treated with DPI 5µM for 1 
hour, subsequently cells were exposed to sera from SSc patients. After SSc 
sera exposition, HPMECs pretreated with DPI showed reduced levels of 
intracellular ROS as compared with cells that did not receive DPI, 
suggesting the implication of NOX in the ROS generation observed in SSc 
sera-exposed cells. 
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4.4. NOX2 is not involved in the increase of intracellular ROS levels 
induced by sera of patients with SSc. 
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Figure 4.3. A specific NOX2 inhibitor (NOXds-tat or gp91ds-tat) was exploited to 
investigate whether NOX2 is related to NOX-derived ROS. HPMECs were treated with 
gp91ds-tat (NOX2 inhibitor) for 1 hour, subsequently with 10% (V/V) of sera of SSc 
patients and HD. Variations in intracellular ROS levels were kinetically determined in a 5-
hour time-course experiment (not shown) and values at 2 hours were used for comparison. 
Fluorescence data were expressed as Relative Fluorescence Units (RFU). ns: non-
significant difference. 
As ROS-generating enzymes, seven NOX members are known so far, NOX1-
5 and DUOX1-2. Previous result indicated that NOX2-mediated increase of 
ROS is induced by sera of SSc patients in HPASMCs [13]. NOX2, also 
known as gp91phox, is the prototype NADPH oxidase and a well-established 
player in the control of endothelial function. We therefore asked whether 
NOX2 might be implicated in the ROS generation observed under our 
experimental condition. To this end, we tested whether the specific NOX2 
inhibitor (NOX2ds-tat or gp91ds-tat) was able to inhibit the increased levels 
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of intracellular ROS elicited by sera of SSc patients. HPMECs were 
pretreated with NOX2ds-tat (or gp91ds-tat) before the exposition to sera from 
SSc patients and the levels of intracellular ROS were measured. Data reported 
in figure 4.3 showed the failure of NOX2ds-tat in downregulating the increase 
of SSc sera-mediated ROS generation, questioning the implication of NOX2 
in the observed oxidative stress. 
To corroborate the above-reported result, we conducted a set of experiments 
using p47-roGFP. p47-roGFP is a fusion protein obtained by the binding of 
p47 (a subunit of NOX2) with the redox sensitive green fluorescence protein 
(roGFP), which is therefore able to assess environmental redox variation 
originated by NOX2 activation. Results reported in figure 4.4 show non-
significant differences among SSc patients and HD in activating NOX2, thus, 
supports previous result and excludes NOX2 implication in SSc sera-
mediated ROS production. 
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Figure 4.4. HPMECs transduced with p47-roGFP (105 cells/mL) were seeded in black 
96-well microplate (Costar, Corning, Inc, NY). Sub-confluent cells were then cultured in 
basal medium containing 10% (V/V) of sera from SSc patients and HD. Variations of p47-
roGFP redox status were kinetically followed for 5 hours and values at 2 hours were used 
for comparison. 
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4.5. Sera of patients with SSc raised COL1A1 promoter activity in 
HPMECs. 
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Figure 4.5. Effect of sera on collagen promoter activation. Sub-confluent HPMECs 
were transduced with lentiviral particles obtained from the pCOL1A1-LV-tGFP and EFα-
LV-FP602 lentivectors, and then cultured in basal medium containing 10% (V/V) of  sera 
from SSc and HD subjects. Variations of COL1A promoter activation were kinetically 
followed for 48 hours. Data are normalized for transduction efficiency by reporting the 
ratio of pCOL1A1-LV-tGFP to EFα-LV-FP602 Relative Fluorescence Units (RFU) 
(Green/Red fluorescence). Results are expressed by mean ± SD. ** p < 0.01: significantly 
different from control group (HD). 
Collagen type I is a key player in both the onset and progression of many 
obliterative vascular diseases including SSc. Therefore, we next wanted to 
determine whether SSc sera possess the capability to increase type I collagen 
production in HPMECs. Collagen type I synthesis was investigated by 
infecting the cells with pCOL1A1-LV-tGFP, a turbo green fluorescence 
protein (tGFP)-based lentiviral vector, which is driven by the human 
COL1A1 gene promoter. 
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Data shown in figure 4.5 indicate that sera of SSc patients significantly 
increased collagen promoter activation during the first 2 hours of exposition, 
thereafter the COL1A1 promoter activity decreased, and remaining stable for 
the entire experimental time-course (48 hours). 
4.6. Sera of patients with SSc enhanced proliferative capacity of 
HPMECs. 
 
Figure 4.6. Effect of sera from SSc patients on HPMEC proliferative capacity. 
HPMECs were starved overnight then treated with sera of SSc patients and HD for 24 
hours. Results are expressed by mean ± SD. * p <0.05: significantly different from control 
group (HD). 
Based on their concentration, ROS can be important modulator of both 
physiological and pathological cell proliferation. To understand whether the 
variations of intracellular ROS may affect HPMEC proliferation, we assessed 
the rate of DNA synthesis in cells exposed to SSc and HD sera. The method 
employed is based on the measurement of BrdU incorporation during DNA 
synthesis. HPMECs were starved overnight then treated with sera of SSc 
patients and HD for 24 hours. In comparison to the sera from HD, SSc sera 
originated a significantly higher proliferative effect on HPMECs (p < 0.05).  
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4.7. Iloprost significantly reduced intracellular ROS levels in HPMECs    
Given the implication of ROS in the SSc sera-elicited effects on HPMECs, we 
asked whether iloprost, a common drug used in the treatment of SSc, might 
exert its therapeutic benefits through an antioxidant effect. As stated 
previously in chapter 3 (Materials and Methods), sera were collected at two 
different time points, the first sampling at the baseline and the second 
sampling after 5 hours of the iloprost intravenous infusion. Intracellular ROS 
levels were kinetically determined in a 6-hour time-course and values at the 
first hour were used for comparison as they represented the higher values of 
the time-course. As reported in figure 4.7, the sera of SSc patients taken 
before iloprost infusion significantly increased ROS levels in HPMECs, while 
sera of SSc patients taken 5 hours after the iloprost infusion significantly 
countered the diseases-associated ROS generation (p < 0.01). 
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                                 (A)                 (B) 
Figure 4.7.  Intracellular ROS levels induced by sera of patients with SSc before and 
after using iloprost. Sub-confluent HPMECs were stimulated with sera of SSc before and 
after using iloprost (SSc pre-iloprost and SSc post-iloprost, respectively). Intracellular 
ROS levels were kinetically determined in a 6-hour time-course (A) and values at first hour 
were used for comparison (B). The results are expressed with mean ± SD. *p < 0.05; ** p 
< 0.01: significantly different from control group (HD). 
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4.8. Iloprost reduced COL1A1 promoter activity in HPMECs 
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Figure 4.8. Effect of SSc sera taken at the baseline and after 5 hours using iloprost on 
collagen promoter activation. Sub-confluent HPMECs were transduced with lentiviral 
particles obtained from the pCOL1A1-LV-tGFP and EFα-LV-FP602 lentivectors, and then 
cultured in basal medium containing 10% (V/V) of sera from SSc (before and after using 
iloprost), and HD subjects. Variations of COL1A promoter activation were kinetically 
followed for 24 hours. Data are normalized for transduction efficiency by reporting the 
ratio of pCOL1A1-LV-tGFP to EFα-LV-FP602 Relative Fluorescence Units (RFU) 
(Green/Red fluorescence). Results are expressed by mean ± SD. ** p <0.01; *** p < 0.001: 
significantly different from control group (HD).  
Given the ability of iloprost in counteracting the disease-associated variation 
of ROS, we asked whether this affect may be paralleled with the inhibition of 
SSc-induced collagen I activation. To this end, the variations of COL1A 
promoter activation were kinetically measured for 24 hours. The result shows 
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type I collagen promoter activity prominently occurred in the first hour. SSs 
serum-induced activation of collagen synthesis was significantly higher 
compared to control group. Interestingly, SSc sera collected after using 
iloprost reduced the collagen synthesis, suggesting this phenomenon as 
potential target of the iloprost therapeutic effect.  
4.9. Sera of SSc patients induces Endothelial-to-Mesenchymal Transition 
Disease-associated vascular damage is usually associated to endothelial 
impairment, which is characterized by endothelial cells (ECs) with less 
proliferative potential and lower angiogenic capability [3]. Surprising, as 
reported in figure 4.6, sera from SSc patients were instead able to increase 
HPMECs proliferation. In this context, the capability of ECs to shift their 
cellular phenotype toward a more fibrotic and proliferation one, namely 
myofibroblast, has been reported [64]. During this transition, called 
Endothelial-to-Mesenchymal Transition (EndMT), the EC leaves its 
physiological state of quiescence, becoming more proliferative and acquiring 
high capability of migration and secreting extracellular matrix components 
[64]. To test whether SSc sera are able to induce the conversion of ECs into 
myofibroblasts, HPMECs were exposed to sera of SSc patients and HD for 72 
hours, and endothelial and fibrotic characteristics were measured by using 
two specific markers of both phenotypes. ECs exposed to SSc sera exhibited a 
decrease in the protein levels of the endothelial characteristic marker - vWF 
(Figure 4.10). Furthermore, consistent with the establishment of a fibrotic 
process, ECs challenged with SSc sera showed an increase in the fibrotic 
markers, α-SMA (Figure 4.9). 
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Figure 4.9. Analysis of endothelial and mesenchymal cell surface markers by Western 
blot analysis. Sub-confluent cells were stimulated with sera of SSc patients and HD for 72 
hours and then processed for immunoblotting as described in the ―Materials and Methods‖. 
α-SMA, α-smooth muscle actin; vWF, von Willebrand factor.  
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5. DISCUSSION 
Recently, many reports underline a possible role of oxidative stress in the 
pathogenesis of SSc. The production of reactive oxygen species (ROS) by 
skin, visceral fibroblasts, and endothelial cells has been suggested as a 
background of this pathology [51, 94, 105]. SSc-associated oxidative stress 
causes both activation and endothelium damage, ultimately leading to 
vascular complications [51]. Consonantly, in vitro exposure of fibroblast to 
sera from SSc patients induces high production of ROS, whose levels are 
correlated with the severity of clinical involvement [98, 109]. As ROS can 
modulate cell activation, and since endothelial cells are the primary target in 
SSc, endothelial dysfunction may be the first pathological event in the 
pathogenesis of SSc-associated vascular disease. By testing the above-
mentioned hypothesis, we demonstrated for the first time that sera from SSc 
patients induce an abnormal ROS production in HPMECs.  
Within the cells, ROS can be generated from different sources including the 
mitochondrial electron transport chain, xanthine oxidase, cyclooxygenase, and 
lipoxygenase. Nonetheless, among all the cellular sources, NADPH oxidases 
are the most important mediators of ligand-mediated ROS production. 
NADPH oxidases (NOX) are multisubunit enzymes that generate superoxide 
by transferring electrons from NADPH to molecular oxygen [50]. In 
phagocytes, ROS originating from NOX participate in bacterial killing, 
whereas in nonphagocytic cells they are required for cellular responses to 
cytokines and growth factors [72]. To investigate whether the observed sera-
induced ROS derive from NOX family, we conducted an experiment 
employing a general NOX inhibitor, diphenylene iodonium (DPI). HPMECs 
were treated with DPI for one hour prior to the treatment of sera from SSc 
patients. The results showed that DPI, potentially by inhibiting NOX, reduced 
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ROS levels in HPMECs (figure 4.2), therefore suggesting an involvement of 
NOX in ROS generation of HPMECs. 
Endothelial cells express four NOX isoforms including the superoxide-
generating enzymes NOX1, NOX2, NOX5 and the hydrogen peroxide-
generating enzyme NOX4 [32]. The three most important NOX isoforms 
related to SSc are NOX1, NOX2, and NOX4 [96]. NOX2 was the first NOX 
isoform to be identified in endothelial cells and, it is likely to be the most 
important in the context of vascular pathology. We therefore asked whether 
NOX2 might be implicated in the ROS generation observed under our 
experimental condition. To this end, we tested whether the specific NOX2 
inhibitor (NOX2ds-tat or gp91ds-tat) was able to inhibit the increased levels 
of intracellular ROS elicited by sera of SSc patients. HPMECs were 
pretreated with NOX2ds-tat (or gp91ds-tat) before the exposition to sera from 
SSc patients and the levels of intracellular ROS were measured. Experiment 
exploiting NOX2 inhibitor did not show any difference between disease- and 
non-disease-related sera. This may indicate that NOX2 is not implicated in 
SSs-elicited ROS increase. In the NOX2, p47phox is a subunit whose 
phosphorylation leads to its movements toward other NOX2 cytoplasmic 
subunits to form the active enzyme complex of NOX2. The active enzyme 
complex works by generating superoxide (O2  ˉ) in response to the ligand-
mediated activation. Notably, p47 exists only in NOX2; hence, we conducted 
a set of experiment using p47-roGFP, a fusion of p47 and redox green 
fluorescence protein to investigate NOX2-generating ROS. Similar to the 
previous reported data, SSc sera were unable to induce significant variation of 
p47-roGFP as compared with HD sera, indicating that NOX2 may not be 
involved in SSc serum-induced ROS. However, in the study of Boin et al., 
NOX2 inhibitor (NOX2ds-tat) pretreatment in HPASMCs inhibited ROS 
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production induced by sera from SSc patients [13]. Although NOX2 is likely 
the most important in the context of vascular pathology, NOX4 is the most 
highly expressed NOX homolog in endothelial cells. Recent evidence 
indicating that the NOX4 may be one of the most important mediators of ROS 
generation in SSc and the potentially beneficial effects of inhibition of NOX4 
activity is a cogent therapeutic approach for SSc-associated tissue fibrosis and 
fibroproliferative vasculopathy [62, 96]. Probably NOX4 plays the prominent 
role in ROS generation in this circumstance and will be therefore the object of 
our future investigation. 
A hallmark characteristic of SSc that distinguishes it from other fibrotic 
disorders is that autoimmunity and vasculopathy precede fibrosis. Moreover, 
fibrosis in SSc affects many organs and accounts for much of the morbidity 
and mortality related to this disease [121]. The progressive tissue 
accumulation of fibrous matrix composes of collagen, elastin, 
glycosaminoglycan, and fibronectin [2]. Fibrosis may be exacerbated by the 
failure of intrinsic mechanisms that normally constrain fibroblast activation 
[35]. The study of Boin et al. demonstrated that sera of SSc patients increased 
COL1A1 promoter activity in HPASMCs [13]. Interestingly, our study also 
supports the hypothesis that serum of SSc patient is a contributory factor in 
increasing collagen synthesis leading to progressive fibrosis in this disease. 
Aside from fibroblasts, the main determinant accounting for the collagen 
synthesis and fibrosis in SSc are smooth muscle cells and endothelial cells, 
which are less-mentioned sources of collagen synthesis in the pathogenesis of 
fibrosis in SSc. A need of further studies on this issue urges at moment, in 
order to be able to reverse or slow the progression of tissue fibrosis or 
substantially modify the natural progression of the disease. 
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A study described a novel mechanism by which ROS may promote a 
profibrotic phenotype in SSc fibroblasts. ROS production and expression of 
type I collagen, a fibrotic marker gene, were significantly higher in SSc, and 
these alterations were accompanied by significantly lower amounts of free 
thiols compared to normal fibroblasts. Treatment of SSc cells with antioxidant 
decreased the amounts of type I collagen, and scavenged ROS in SSc 
fibroblasts [119]. Likewise, our results indicated that SSc sera induce 
increased ROS generation and collagen promoter activity. Increase in ROS 
levels in HPMECs may cause the elevated activation of collagen promoter. 
Consistently with other studies, our work collectively provides strong support 
for the participation of ROS in the development of exaggerated fibrotic 
responses in SSc.  
At physiological levels, cellular ROS control cell growth and differentiation 
regulating the activity of enzymes, mediating inflammation, stimulating 
cytokine production and eliminating pathogens and foreign particles. On the 
other hand, if present in excessive levels, ROS cause the damage of cellular 
components, including lipids and membranes, proteins and nucleic acids, and 
ultimately inducing cell transformation. Unexpectedly, rather than eliciting 
cell death, the observed SSc-ROS generation was able to accentuate it. SSc is 
a fibro-proliferative disease characterized by the abnormal proliferation and 
extracellular matrix secretion of most of the involved cells [60]. Nevertheless, 
the above-mentioned aspect, namely Endothelial-to-Mesenchymal Transition 
(EndMT) in the case of ECs, has never been investigated a molecular level in 
SSc disease.  
It was hypothesized that endothelial cells undergoing EndMT may contribute 
to endothelial dysfunction and the population of activated mesenchymal cells 
in fibrotic and chronic inflammatory disorders, including inflammatory bowel 
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disease, cardiac fibrosis, and portal hypertension [48]. In the pathogenesis of 
SSc, one of the most characteristic histopathologic alterations is a severe 
fibroproliferative vasculopathy. The alteration in the small arterioles of 
parenchymal organs, such as the lungs and the kidneys, is characterized by the 
subendothelial accumulation of activated fibroblasts or myofibroblasts and the 
production of abundant fibrotic tissue. The origin of mesenchymal cells 
responsible for the fibrotic microvascular occlusion in SSc is not known, but 
recent studies have suggested that at least some of these cells may result from 
EndMT [64]. Under the conversion of endothelium into mesenchyme, 
endothelial cells undergo morphological alterations and loss of cell-surface 
markers. Our result for the first time indicated the presence of EndMT in 
normal HPMECs exposed to sera of SSc patients. Indeed, the expression of 
vWF, a specific endothelial cell marker, was gradually replaced by α-SMA, a 
mesenchymal or myofibroblastic marker. The acquisition of α-SMA is a 
prominent functional feature of myofibroblasts that changes endothelial 
functionality. Phenotypic transformation of ECs leading to decreased levels of 
endothelial adhesion proteins, which allow cell-to-cell separation and 
generate the spindle-shaped, fibroblast-like phenotype, which is strongly 
potentiated by the overexpression of α-SMA stress fibers [88].  Loss of an 
integral endothelial barrier is believed to contribute to the activation and 
proliferation of the underlying vascular SMCs and fibroblasts, thus 
contributing to vascular remodeling [48]. This finding contributes to the 
literature of etiological mechanism of SSc-associated vascular damage, as 
well as suggests a potential therapeutic target to inhibit obliterative vascular 
disorder and tissue fibrosis.  
Iloprost, an analogue of natural prostacyclin (PgI2), is widely used in SSc for 
the treatment of severe RP and ischemic ulcers due to its powerful vasodilator 
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and anti-aggregant effect. Iloprost is effective in the treatment of RP 
secondary to SSc at decreasing the frequency and severity of attacks and 
preventing or healing digital ulcers [36, 122]. There is evidence that iloprost 
attenuates oxidative damage induced by ischemia-reperfusion phenomenon. 
Ferrari et al. demonstrated that pretreatment with iloprost improved the 
functional recovery of the myocardium and attenuated the occurrence of 
oxidative stress on rabbit isolated hearts. Similarly, other studies have showed 
that iloprost reduced oxidative stress in ischemia-reperfusion model of 
skeletal muscle, brain, and renal tissue [122].  
Although some studies investigating the effect of iloprost on oxidative stress 
and collagen synthesis have been published, very little is known concerning 
the molecular mechanism underlying this effect. To our knowledge, this is the 
first study employing the serum of SSc patient taken after treatment with 
intravenous iloprost and investigates its effect on pulmonary endothelial cells. 
Our results showed that SSc sera post-iloprost significantly reduced ROS 
levels in HPMECs (figure 4.7). A study of Erre et al. demonstrated that a 
cycle of five days of iloprost infusion at standard dosage leads to a significant 
reduction of 8-iso prostaglandin-F2α (8-iso-PGF2α) urinary levels in the same 
SSc patients. As noted, 8-iso PGF2α is a biochemically stable member of the 
family of F2-isoprostanes, free radical catalyzed products of lipid 
peroxidation that are considered the best reliable markers of oxidative stress 
in vivo [36]. Apparently, recent studies indicate that dietary and 
pharmacological antioxidants can be used as therapeutic targets for SSc [51]. 
This study thereby supports the evidence that iloprost could be used as 
antioxidant therapy aside from its vasodilatory effect in SSc patients.  
Scleroderma patients receiving iloprost as a treatment for severe Raynaud‘s 
phenomenon report reduction in skin tightness, suggesting that this drug 
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inhibits skin fibrosis [116]. Our results showed that HPMECs treated with 
sera after iloprost infusion markedly reduce type I collagen synthesis.  
Stratton et al. demonstrated that iloprost infusion caused a remarkable 
decrease in dermal CTGF levels. CTGF is a well-known profibrotic cytokine, 
which acts in concert with TGF-β to drive the overproduction of collagen 
[15]. Consistent with this, Gomez-Arroyo et al. also indicated in vitro, cardiac 
fibroblasts treated with iloprost showed a reduction in TGF-β1-induced CTGF 
expression. Iloprost significantly induced metalloproteinase-9 gene 
expression and activity and increased the expression of autophagy genes 
associated with collagen degradation [47]. In our stydy, iloprost infusion in 
SSc patients might attenuate CTGF levels in SSc sera preceding the 
alleviation of type I collagen synthesis.  Indeed, in SSc, skin and visceral 
fibroblasts spontaneously produce large amounts of ROS that trigger collagen 
synthesis [51]. Therefore, the decrease in ROS levels induced by post-iloprost 
sera infusion as shown in previous result may explain the reduction of type I 
collagen synthesis in pulmonary endothelial cells.  
We also found that sera after being treated iloporost suppressed type I 
collagen synthesis at the first 2 hours after treatment and that this effect was 
lost by 8 hours (24 hour-time course mesurement). These observations have 
implications for the clinical use of iloprost, suggesting that a brief exposure to 
the drug two or three times a day might be sufficient to maintain suppression 
of collagen promoter activity. The results of the present study suggest that 
iloprost infusion could have beneficial effects in addition to its properties as a 
vasodilator.  
Although this work provides some findings concerning the etiology of SSc-
associated vascular damage, at the same time it opens new questions and 
challenges. For instance, whether SSc sera induced-oxidative stress is the 
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mediator of EndMT in SSc and iloprost may counteract such a phenomenon 
remains unelucidated. Further investigation needs to be conducted to discover 
the causative factors leading to the conversion of ECs into myofibroblasts in 
SSc. Therefore, whether there is a link between oxidative stress and EndMT 
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CONCLUSION 
With the intent to investigate the molecular mechanisms underlying vascular 
damage in systemic sclerosis (SSc), we achieved some pilot results.  
For the first time we report that SSc sera significantly increased ROS levels, 
proliferation, and collagen synthesis in human pulmonary microvascular 
endothelial cells, as compared with sera from Healthy Donor (HD). The 
observed effects appear to be mediated by NADPH oxidases suggesting the 
potential for an antioxidant therapeutic approach. Interestingly, SSc sera taken 
after 5 hours of iloprost infusion could attenuate ROS levels and collagen 
synthesis. Thus, our study suggests that, aside from its well-known 
vasodilatory effect, an antioxidant-mediated effect could be part of the 
mechanisms of action of this drug. Sera from SSc patients also induced 
EndMT indicating this phenotypic shift as an important etiological 
mechanism of SSc-associated vascular damage, as well as a potential 
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